396 related articles for article (PubMed ID: 25454706)
1. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
Gisbert JP; Romano M; Molina-Infante J; Lucendo AJ; Medina E; Modolell I; Rodríguez-Tellez M; Gomez B; Barrio J; Perona M; Ortuño J; Ariño I; Domínguez-Muñoz JE; Perez-Aisa Á; Bermejo F; Domínguez JL; Almela P; Gomez-Camarero J; Millastre J; Martin-Noguerol E; Gravina AG; Martorano M; Miranda A; Federico A; Fernandez-Bermejo M; Angueira T; Ferrer-Barcelo L; Fernández N; Marín AC; McNicholl AG
Dig Liver Dis; 2015 Feb; 47(2):108-13. PubMed ID: 25454706
[TBL] [Abstract][Full Text] [Related]
2. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
[TBL] [Abstract][Full Text] [Related]
3. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
[TBL] [Abstract][Full Text] [Related]
4. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients.
Gisbert JP; Pérez-Aisa A; Bermejo F; Castro-Fernández M; Almela P; Barrio J; Cosme A; Modolell I; Bory F; Fernández-Bermejo M; Rodrigo L; Ortuño J; Sánchez-Pobre P; Khorrami S; Franco A; Tomas A; Guerra I; Lamas E; Ponce J; Calvet X;
J Clin Gastroenterol; 2013 Feb; 47(2):130-5. PubMed ID: 22647827
[TBL] [Abstract][Full Text] [Related]
5. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.
Gisbert JP; Bermejo F; Castro-Fernández M; Pérez-Aisa A; Fernández-Bermejo M; Tomas A; Barrio J; Bory F; Almela P; Sánchez-Pobre P; Cosme A; Ortiz V; Niño P; Khorrami S; Benito LM; Carneros JA; Lamas E; Modolell I; Franco A; Ortuño J; Rodrigo L; García-Durán F; O'Callaghan E; Ponce J; Valer MP; Calvet X;
Am J Gastroenterol; 2008 Jan; 103(1):71-6. PubMed ID: 17764498
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
Chung KH; Lee DH; Jin E; Cho Y; Seo JY; Kim N; Jeong SH; Kim JW; Hwang JH; Shin CM
Gut Liver; 2014 Nov; 8(6):605-11. PubMed ID: 25368747
[TBL] [Abstract][Full Text] [Related]
8. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
10. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ
Korean J Gastroenterol; 2018 Apr; 71(4):196-203. PubMed ID: 29684968
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
[TBL] [Abstract][Full Text] [Related]
12. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
[TBL] [Abstract][Full Text] [Related]
13. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG;
Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798
[TBL] [Abstract][Full Text] [Related]
14. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
Almeida N; Romãozinho JM; Donato MM; Luxo C; Cardoso O; Cipriano MA; Marinho C; Sofia C
Helicobacter; 2014 Apr; 19(2):90-7. PubMed ID: 24506175
[TBL] [Abstract][Full Text] [Related]
15. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea.
Kang KK; Lee DH; Oh DH; Yoon H; Shin CM; Park YS; Kim N; Jung HC
World J Gastroenterol; 2014 Jun; 20(22):6932-8. PubMed ID: 24944485
[TBL] [Abstract][Full Text] [Related]
16. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial.
Georgopoulos S; Papastergiou V; Xirouchakis E; Laoudi F; Lisgos P; Spiliadi C; Papantoniou N; Karatapanis S
J Clin Gastroenterol; 2013 Mar; 47(3):228-32. PubMed ID: 22858517
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Zheng Q; Pan Y; Zhang L; Xiao SD
Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
[TBL] [Abstract][Full Text] [Related]
18. Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates.
Rakici H; Akdoğan RA; Bedir R; Copur A; Yilmaz A
J Dig Dis; 2014 Sep; 15(9):508-13. PubMed ID: 24980811
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781
[TBL] [Abstract][Full Text] [Related]
20. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures.
Gisbert JP; Castro-Fernandez M; Perez-Aisa A; Cosme A; Molina-Infante J; Rodrigo L; Modolell I; Cabriada JL; Gisbert JL; Lamas E; Marcos E; Calvet X
Aliment Pharmacol Ther; 2012 Apr; 35(8):941-7. PubMed ID: 22372560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
